Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,360 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (645)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03812874 | A Study of PTX-9908 Injection for Non-resectable HCC with TACE | recruiting | Phase 1 / Phase 2 | 50 | TCM Biotech International Corp.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05321992 | Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand(eCHEC) | recruiting | N/A | 480 | McMaster UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06301399 | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06628661 | Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 cm and Microvascular Invasion | recruiting | — | 3,000 | Chang Gung Memorial HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06694636 | Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma | recruiting | N/A | 5 | Zhongda HospitalOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06313190 | Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)(HSBRT2402) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05072041 | Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma | recruiting | N/A | 150 | Next Biomedical Co., Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05887661 | Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy | recruiting | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | recruiting | Phase 2 | 38 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer(ASPIRE) | recruiting | Phase 2 / Phase 3 | 600 | Panbela Therapeutics, Inc.INDUSTRY | 10 | Nov 6, 2024 | clinicaltrials |
| NCT06461624 | Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06595108 | Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma(A-BEST) | recruiting | N/A | 33 | Yonsei UniversityOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06669377 | TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT. | recruiting | — | 444 | Zhongda HospitalOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06664996 | Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT | recruiting | Phase 2 | 33 | West China HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT05851534 | Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas(PROMISE-P) | recruiting | N/A | 2,575 | Maastricht University Medical CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05744219 | Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial(IRIS) | recruiting | Phase 3 | 338 | Jon UnossonOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06041009 | Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations | recruiting | — | 2,100 | Qilu Hospital of Shandong UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06649474 | Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1(HEPATOXALI) | recruiting | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04183712 | Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA | recruiting | Phase 2 | 102 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05882370 | TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | recruiting | Phase 2 | 30 | Fei GaoOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06569498 | Neoadjuvant Triple Therapy for Resectable HCC(TALENP001) | recruiting | — | 20 | Fujian Provincial HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06602011 | Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) | recruiting | — | 20 | Fujian Provincial HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05440864 | Durvalumab and Tremelimumab in Resectable HCC((NEOTOMA)) | recruiting | Phase 2 | 28 | University Health Network, TorontoOTHER | 3 | Oct 10, 2024 | clinicaltrials |
| NCT06623474 | Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma | recruiting | — | 900 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06632093 | HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC | recruiting | — | 84 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04571294 | Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy(PALN) | recruiting | N/A | 180 | Humanitas Hospital, ItalyOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06624098 | Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma | recruiting | N/A | 22 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06617000 | A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | recruiting | Phase 1 | 38 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06061276 | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC | recruiting | N/A | 40 | Sun Yat-sen UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06593964 | TACE With Thermosensitive Nanogel Versus Embosphere for HCC | recruiting | N/A | 188 | Zhongda HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06601231 | To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.(ADRENALIN) | recruiting | — | 1,000 | Erasmus Medical CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06581315 | Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma | recruiting | N/A | 204 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06041477 | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC(HAIC) | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06561399 | Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) | recruiting | — | 28 | Fujian Provincial HospitalOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06559761 | Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research | recruiting | — | 500 | Chinese PLA General HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06079346 | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer(STOP-PC) | recruiting | Phase 2 / Phase 3 | 455 | Oncotelic Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06550921 | Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma | recruiting | N/A | 60 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06519578 | Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma | recruiting | N/A | 1,115 | RenJi HospitalOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06454578 | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | recruiting | Phase 2 | 30 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06518434 | A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients(CanHep) | recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05844046 | Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients(MONTBLANC) | recruiting | Phase 2 | 83 | Enrico De ToniOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06498622 | Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab | recruiting | Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 12, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06478927 | Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib | recruiting | N/A | 22 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04952272 | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors | recruiting | Phase 1 | 50 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03198546 | GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2024source: clinicaltrials